ViiV Says Latest Data Back Two-Drug Approach, Plans Year-End Fostemsavir Filing

 
• By Sten Stovall

ViiV Healthcare research head tells Scrip she expects Dovato’s latest data presentation should boost the two-drug regimen’s uptake, and that the AIDS-fighter plans a US FDA filing of its investigational candidate fostemsavir before end-2019 following good Phase III BRIGHTE results.

HIV virus
Dovato and fostemsavir Data presented at International AIDS Society Meeting in Mexico • Source: Shutterstock

More from Business

More from Scrip